Abstract
Mass spectrometry (MS) is one of the key analytical technology on which the emerging ‘‘-omics’’ approaches are based. It may provide detection and quantization of thousands of proteins and biologically active metabolites from a tissue, body fluid or cell culture working in a ‘‘global’’ or ‘‘targeted’’ manner, down to ultra-trace levels. It can be expected that the high performance of MS technology, coupled to routine data handling, will soon bring fruit in the request for a better understanding of human diseases, leading to new molecular biomarkers, hence affecting drug targets and therapies.
In this review, we focus on the main advances in the MS technologies, influencing genomics, transcriptomics, proteomics, lipidomics and metabolomics fields, up to the most recent MS applications to meta-omic studies.
Keywords: Mass spectrometry, MS, MS-based genomics, MS-based proteomics, MS-based metabolomics, MS-based lipidomics, Meta-omics.
Current Organic Chemistry
Title:The Role of Mass Spectrometry in the “Omics” Era
Volume: 17 Issue: 23
Author(s): Francesco Di Girolamo, Isabella Lante, Maurizio Muraca and Lorenza Putignani
Affiliation:
Keywords: Mass spectrometry, MS, MS-based genomics, MS-based proteomics, MS-based metabolomics, MS-based lipidomics, Meta-omics.
Abstract: Mass spectrometry (MS) is one of the key analytical technology on which the emerging ‘‘-omics’’ approaches are based. It may provide detection and quantization of thousands of proteins and biologically active metabolites from a tissue, body fluid or cell culture working in a ‘‘global’’ or ‘‘targeted’’ manner, down to ultra-trace levels. It can be expected that the high performance of MS technology, coupled to routine data handling, will soon bring fruit in the request for a better understanding of human diseases, leading to new molecular biomarkers, hence affecting drug targets and therapies.
In this review, we focus on the main advances in the MS technologies, influencing genomics, transcriptomics, proteomics, lipidomics and metabolomics fields, up to the most recent MS applications to meta-omic studies.
Export Options
About this article
Cite this article as:
Girolamo Di Francesco, Lante Isabella, Muraca Maurizio and Putignani Lorenza, The Role of Mass Spectrometry in the “Omics” Era, Current Organic Chemistry 2013; 17 (23) . https://dx.doi.org/10.2174/1385272817888131118162725
DOI https://dx.doi.org/10.2174/1385272817888131118162725 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Relaxin as a Cardiovascular Hormone: Physiology, Pathophysiology and Therapeutic Promises
Cardiovascular & Hematological Agents in Medicinal Chemistry Statins Attenuate Fibrotic Manifestations of Cardiac Tissue Damage
Current Molecular Pharmacology Editorial [Hot Topic: Biochemical and Clinical Relevance of Hyperuricaemia (Executive Editor: Dimitri P. Mikhailidis Associate Editor: Stella S. Daskalopoulou)]
Current Pharmaceutical Design Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era
Current HIV Research The L-Type Ca2+ Channel as a Therapeutic Target in Heart Disease
Current Medicinal Chemistry Clinical Efficacy and Effectiveness of Ursodeoxycholic Acid in Cholestatic Liver Diseases
Current Clinical Pharmacology A Review of Feature Extraction from ECG Signals and Classification/ Detection for Ventricular Arrhythmias
Recent Advances in Computer Science and Communications Cardiovascular Effects of Methotrexate in Rheumatoid Arthritis Revisited
Current Medicinal Chemistry Marine n-3 Fatty Acids for Cardiovascular Risk Reduction and Disease Control in Rheumatoid Arthritis: “Kill Two Birds with One Stone”?
Current Pharmaceutical Design Primary and Secondary Stroke Prevention with Antiplatelet Drugs
Current Pharmaceutical Design Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents
Current Drug Targets Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Current Pharmaceutical Design Recognizing Severe Adverse Drug Reactions: Two Case Reports After Switching Therapies to the Same Generic Company
Current Drug Safety Editorial: Understanding Basic Muscle Electrophysiology While Keeping an Eye on Diseases of the Heart, Lung and Blood
Recent Patents on Cardiovascular Drug Discovery Adherence to Cardiac Practice Guidelines in the Management of Non-ST-Elevation Acute Coronary Syndromes: A Systematic Literature Review
Current Cardiology Reviews HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview
Current Drug Metabolism High Blood Pressure and the Risk of Stroke
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Biomarkers Linking PCB Exposure and Obesity
Current Pharmaceutical Biotechnology Effects of Drugs, Phytoestrogens, Nutrients and Probiotics on Endothelial Dysfunction in the Estrogen-Deficient State
Current Pharmaceutical Design